‘This is misleading and false’, the government denied the claims of early approval of Covaxin under pressure

Bharat Biotech Covaxin: India’s Health Ministry on Thursday (November 17) has called media reports wrong, which claimed that Kovid-19 vaccine, Covaxin maker Bharat Biotech has developed the vaccine. There was no external pressure to develop rapidly. It has also been claimed in the reports that many irregularities were found in the three phases of the clinical trial conducted for the vaccine. Scientific approach and prescribed norms have been followed for granting government license to Covaxin as a corona vaccine, said Health Ministry.

Bharat Biotech, the company making Covaxin, said, millions of doses of Covaxin have been applied worldwide and it has performed tremendously and its negative effects were very less. Bharat Biotech said, "There have been no reported cases of myocarditis or thrombocytopenia (low platelet count) due to the vaccine.

HealthForAll

yths 𝗩s ท฿cts

✅ Media Reports claiming regulatory approval for Covaxin was rushed due to Political Pressure are Misleading and Fallacious https://t.co/K4EwCFwxD1 pic.twitter.com/xGeeEizYXT

— Ministry of Health (@MoHFW_INDIA) November 17, 2022

"text-align: justify;">Government called the reports wrong
Government of India, while replying to this regarding the approval of the vaccine, said, "It is being claimed in some media reports that due to political pressure, there was haste in giving regulatory approval to the vaccine. All these reports are false, misleading and incorrect. The government said, scientific approach and prescribed norms have been followed to approve the emergency use of the vaccine as a corona vaccine.

Approved after necessary information
The unscientific changes in the clinical trial of Covaxin, which are being claimed in the news, have been submitted by Bharat Biotech to the Central Drugs Standard Control Organization (CDSCO). The information was collected following the process of the Central Drugs Standard Control Organization and with the approval of the Directorate General of Commercial Intelligence and Statistics  (DGCI).

Union Health Ministry said, "Based on additional data provided by Bharat Biotech and interim efficacy and safety analyzes by the  Securities and Exchange Commission of CDSCO, the condition for use of anti-COVID-19 vaccine in clinical trial mode was lifted on March 11, 2021 .

We condemn the targeted narrative against COVAXIN put forth by a select few individuals and groups who have no expertise in vaccines or vaccinology. It is well known that they helped perpetuate misinformation and fake news throughout the pandemic: BharatBiotech pic.twitter.com/ilnxVBoot0

— ANI (@ANI) November 17, 2022

"text-align: justify;"> Based on the recommendations of the subject expert committee of CDSCO, the national regulator had allowed the use of other anti-Kovid-19 vaccines including Covaxin in emergency with various conditions and restrictions. CDSCO’s Subject Expert Committee consists of experts in Pulmonology, Immunology, Microbiology, Pharmacology, Pediatrics, Internal Medicine, etc.

Read also:COVID Update: Less than 1,000 cases of corona being registered since last 5 days, improvement seen in vaccine takers

Leave a Comment